POLD1
ENSG00000062822
Target class
Enzyme
Chromosome
19
Approved drugs
4
Clinical candidates (approved and in development)
6
- Approved drugs
- 4
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 6
- Chemical probe available
- No
- Other names
- CDC2
- Target name
- POLD1
- Gene name
- DNA polymerase delta 1, catalytic subunit
- Gene symbol
- POLD1
- Previous gene symbols
- POLD
- Protein name
- DNA polymerase delta catalytic subunit (EC 2.7.7.7) (3'-5' exodeoxyribonuclease) (EC 3.1.11.-) (DNA polymerase subunit delta p125)
- Gene biotype
- Protein coding
- Gene family
- DNA polymerases
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 59.13
- Tissue specificity (Gini)
- 0.383
- Tissue specificity (tau)
- 0.831
- KEGG gene identifiers
- hsa:5424
- Protein interaction confidence
- 0.875669
- Protein interaction partners
- 127
- R-HSA-110314
- R-HSA-174411
- R-HSA-174414
- R-HSA-174417
- R-HSA-174437
- R-HSA-2564830
- R-HSA-5358565
- R-HSA-5358606
- R-HSA-5651801
- R-HSA-5656169
- R-HSA-5685942
- R-HSA-5696397
- R-HSA-5696400
- R-HSA-6782135
- R-HSA-6782210
- R-HSA-69091
- R-HSA-69166
- R-HSA-69183
- End position
- 50418018
- Start position
- 50384204
- Chromosome
- 19
- Strand
- Forward
- Nucleus . Note=Colocalizes with PCNA and POLD3 at S phase replication sites (PubMed:11595739). After UV irradiation, recruited to DNA damage sites within 2 hours, independently of the cell cycle phase, nor on PCNA ubiquitination. This recruitment requires POLD3, PCNA and RFC1-replication factor C complex (PubMed:20227374, PubMed:22801543). .
- Nucleoplasm
- PubMed 11595739
- PubMed 20227374
- PubMed 22801543
- Tissue specificity (tau)
- 0.831274
- Expression inequality (Gini)
- 0.382908
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 59.13
- Testis
- 30.12
- Thyroid
- 22.07
- Spleen
- 21.59
- Uterus
- 20.17
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes59.13
- Testis30.12
- Thyroid22.07
- Spleen21.59
- Uterus20.17
- Lung19.6
- Cervix - Ectocervix17.04
- Cervix - Endocervix16.71
- Small Intestine - Terminal Ileum15.53
- Cells - Cultured fibroblasts15.5
- Nerve - Tibial15.48
- Ovary14.77
- Vagina14.39
- Esophagus - Mucosa14.09
- Fallopian Tube14.02
- Skin - Not Sun Exposed (Suprapubic)13.67
- Skin - Sun Exposed (Lower leg)13
- Colon - Transverse12.31
- Bladder11.95
- Prostate11.94
- Brain - Cerebellum11.91
- Colon - Sigmoid11.53
- Breast - Mammary Tissue11.35
- Brain - Cerebellar Hemisphere11.22
- Minor Salivary Gland10.93
And 29 more, listed on the interactive page.
- GO:0000731
- GO:0006260
- GO:0006261
- GO:0006281
- GO:0006287
- GO:0006297
- GO:0009411
- GO:0055089
- GO:0070987
- GO:0071897
- GO:0000109
- GO:0000781
- GO:0005634
- GO:0005654
- GO:0016020
- GO:0043625
- GO:0003677
- GO:0003682
- GO:0003684
- GO:0003887
- GO:0005515
- GO:0034061
Related records
Trials (4,736)
- (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma
- (PM-01) IMPRIME PGG® With BTH1704 and Gemcitabine for Advanced Pancreatic Cancer
- 1911GCCC: Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy
- 2 Arm Study of Clofarabine IV in MDS Patients
- 2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)
- 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
- 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
- ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma
- 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
- 24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC
- 2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen
- 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia
- 3-AP and Gemcitabine as Second-Line Therapy in Treating Patients With Stage III or Stage IV Recurrent Non-Small Cell Lung Cancer
- 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
- 3-AP and Gemcitabine in Treating Patients With Metastatic Non-Small Cell Lung Cancer
- 3-AP and Gemcitabine in Treating Patients With Recurrent, Unresectable, or Metastatic Pancreatic Cancer
- 3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer
- 3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
- 3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome
Drugs (7)
- Aspacytarabine DNA polymerase (alpha/delta/epsilon) inhibitor
- Clofarabine DNA polymerase (alpha/delta/epsilon) inhibitor
- Cytarabine DNA polymerase (alpha/delta/epsilon) inhibitor
- Fludarabine phosphate DNA polymerase (alpha/delta/epsilon) inhibitor
- Gemcitabine DNA polymerase (alpha/delta/epsilon) inhibitor
- Gemcitabine hydrochloride DNA polymerase (alpha/delta/epsilon) inhibitor
- Troxacitabine DNA polymerase (alpha/delta/epsilon) inhibitor